BrainStorm Cell Therapeutics Plans Q1 Results Conference Call

BrainStorm Cell Therapeutics to Update on First Quarter Results

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a pioneer in developing adult stem cell therapies for neurodegenerative diseases, is set to hold a conference call to discuss its financial results for the first quarter. The call is expected to provide important insights into the company’s performance and strategic direction.

Conference Call Details

The conference call is scheduled for 8:30 a.m. Eastern Time. During this event, Chaim Lebovits, President & CEO of BrainStorm, will present the company updates followed by a question and answer session. Other key personnel, including Bob Dagher, M.D., Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate.

How to Participate

Shareholders and interested parties can submit questions ahead of the call to ensure thorough coverage during the Q&A. Questions should be sent in advance. Details on how to access the call are shared broadly for convenience.

To join the conference call, participants can dial:
Toll-Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 621608

Accessing the Replay

For those who cannot attend the live call, a replay will be available for 14 days following the presentation. The replay numbers are:
Toll-Free: 877-481-4010
International: 919-882-2331
Response Passcode: 52457

About BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc. is committed to developing innovative autologous therapies that target debilitating neurodegenerative diseases. Utilizing their specialized platform, NurOwn, BrainStorm aims to utilize mesenchymal stem cells that create neurotrophic factors to enhance patient outcomes.

Current Developments

BrainStorm’s flagship product, NurOwn, is under clinical evaluation as a potential treatment for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the FDA and EMA. Ongoing clinical trials aim to validate its effectiveness and safety, positioning BrainStorm at the forefront of regenerative therapies.

The company recently announced the completion of a Phase 3 trial and is gearing up for a confirmatory Phase 3b trial under a Special Protocol Assessment with the FDA. This progress indicates significant momentum in their clinical strategy and provides hope for patients facing ALS and other neurodegenerative conditions.

Additionally, BrainStorm has expanded its research to multiple sclerosis, where it conducted a Phase 2 open-label trial with promising initial outcomes. The company is also venturing into exosome-based platforms to enhance therapy delivery methods.

Investor Relations and Media Contact

For more information, investors can reach out to:
Michael Wood
Phone: +1 646-597-6983
Email: [email protected]

For media inquiries, please contact:
Uri Yablonka, Chief Business Officer
Phone: +1 917-284-2911
Email: [email protected]

Frequently Asked Questions

What is the purpose of the conference call?

The conference call aims to discuss BrainStorm's financial results for the first quarter and provide company updates.

Who will present during the conference call?

President & CEO Chaim Lebovits will lead the presentation, accompanied by key executives, including the Chief Medical Officer.

How can I submit a question for the conference call?

Questions can be sent in advance to the provided email address prior to the specified deadline.

What products does BrainStorm Cell Therapeutics focus on?

BrainStorm is known for its innovative treatments for neurodegenerative diseases, particularly through its NurOwn platform.

Where can I find more information about BrainStorm?

Visit BrainStorm Cell Therapeutics' official website to explore more about their research and products.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.